Jazz Pharmaceuticals plc - Asset Resilience Ratio

Latest as of March 2026: 8.68%

Jazz Pharmaceuticals plc (J7Z) has an Asset Resilience Ratio of 8.68% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Jazz Pharmaceuticals plc to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€1.03 Billion

≈ $1.20 Billion USD Cash + Short-term Investments

Total Assets

€11.86 Billion

≈ $13.87 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Jazz Pharmaceuticals plc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Jazz Pharmaceuticals plc total assets.

Liquid Assets Composition Over Time

This chart breaks down Jazz Pharmaceuticals plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Jazz Pharmaceuticals plc's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€1.03 Billion	8.68%
Total Liquid Assets	€1.03 Billion	8.68%

Asset Resilience Insights

Limited Liquidity: Jazz Pharmaceuticals plc maintains only 8.68% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Jazz Pharmaceuticals plc Industry Peers by Asset Resilience Ratio

Compare Jazz Pharmaceuticals plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Jazz Pharmaceuticals plc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Jazz Pharmaceuticals plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	9.01%	€1.05 Billion ≈ $1.23 Billion	€11.66 Billion ≈ $13.63 Billion	+4.18pp
2024-12-31	4.83%	€580.00 Million ≈ $678.08 Million	€12.01 Billion ≈ $14.04 Billion	+3.78pp
2023-12-31	1.05%	€120.00 Million ≈ $140.29 Million	€11.39 Billion ≈ $13.32 Billion	--
2022-12-31	0.00%	€0.00 ≈ $0.00	€10.84 Billion ≈ $12.67 Billion	--
2021-12-31	0.00%	€0.00 ≈ $0.00	€12.30 Billion ≈ $14.38 Billion	--
2020-12-31	16.45%	€1.07 Billion ≈ $1.26 Billion	€6.54 Billion ≈ $7.64 Billion	+8.50pp
2019-12-31	7.94%	€440.00 Million ≈ $514.41 Million	€5.54 Billion ≈ $6.48 Billion	-1.95pp
2018-12-31	9.90%	€515.00 Million ≈ $602.09 Million	€5.20 Billion ≈ $6.08 Billion	+5.70pp
2017-12-31	4.20%	€215.00 Million ≈ $251.36 Million	€5.12 Billion ≈ $5.99 Billion	+2.95pp
2016-12-31	1.25%	€60.00 Million ≈ $70.15 Million	€4.80 Billion ≈ $5.61 Billion	--

pp = percentage points

About Jazz Pharmaceuticals plc

F:J7Z Germany Biotechnology

Market Cap

$15.26 Billion

€13.05 Billion EUR

Market Cap Rank

#1960 Global

#412 in Germany

Share Price

€208.00

Change (1 day)

-2.26%

52-Week Range

€108.25 - €225.90

All Time High

€225.90